Podcasts about recursion pharmaceuticals

On this week's episode, Sam Fazeli, John Maraganore, Nina Kjellson and Matt Gline dig into an in-depth discussion on the Trump Administration's recent executive order aimed at lowering drug prices as part of a broader “Most Favored Nation.” The group discusses the 30-day ultimatum, the 180- days for negotiations and concerns that biotechs may not be adequately represented at the table. The conversation shifts to PBMs, noting that there's growing support for banning spread pricing and requiring more reporting from PBMs. The group also touches on orphan drugs, sharing that there's bipartisan support to exempt orphan drugs from IRA negotiations. Pharma's talk of investment in AI is also overviewed. Next, the group discusses Recursion Pharmaceuticals' Q1 pipeline reorganization and Galapagos reversing its decision to split in two. CMS guidance on IRA Part B negatively impacted Halozyme Therapeutics and J&J, raising questions about the classifications of subQ formulations as different drugs despite sharing the same active ingredient. The episode ends with a discussion on CytomX Therapeutics' resurrection, including its stock price jump. *This episode aired on May 16, 2025.

Send us a textDr. Martin Brenner, DVM, Ph.D. is Chief Executive Officer and Chief Scientific Officer of iBio ( https://ibioinc.com/team/martin-brenner-dvm-ph-d/ ), a biotech company developing the next generation of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function, as well as a pipeline of therapeutic candidates in immuno-oncology for some of the most-difficult-to-treat cancers, including solid tumors in lung, colorectal, and breast cancer, head and neck cancer, pancreatic cancer and glioblastoma, a fast-growing brain tumor. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories. Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020. Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need. Prior to his time at Recursion, Dr. Brenner was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases. Prior to Stoke, Dr. Brenner was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team's research on diabetes and nonalcoholic steatohepatitis (NASH). Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca. In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.Dr. Brenner has a DVM, Veterinary Medicine, Ludwig-Maximilians-Universität München and a Ph.D., Pharmacology  Tieraerztliche Hochschule Hannover.#MartinBrenner #iBio #Cardiometabolic #Obesity #Medicines #WeightLoss #MetabolicHealth #ImmunoOncology #GLP1 #BispecificAntibodies #ArtificialIntelligence #TransformingGrowthFactorBeta #Myostatin #ActivinA #ActivinE #MuscleMass #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Today's guest is Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals.Recursion is widely recognized as one of the most visible—and so far, most successful—companies to emerge from the tech-bio movement. Many consider it the current industry leader.It has become an iconic name in the field of artificial intelligence for drug discovery.TPM E44 highlights >⁠⁠⁠⁠⁠⁠⁠Episode 44 links:Najat Khan on LinkedInRecursion

Kirk Spano and Bhavneesh Sharma talk biotech, pharma, the unpredictable FDA and why complete response letters are a good contrarian buying opportunity (2:10). Understanding investment potential and unmet medical needs (11:10). CRISPR technology, gene editing disappointment (17:00). How AI is revolutionizing drug discovery (30:20). Why Kirk likes Pfizer, Bristol-Myers and Bhavneesh likes Recursion Pharmaceuticals. (38:35).Episode transcriptsShow Notes:The Role Of AI In PharmaceuticalsKirk Spano's Margin of Safety InvestingBhavneesh Sharma's Vasuda Healthcare AnalyticsFor full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

A Spotify offline zenehallgatási funkciót vezetett be ITBusiness     2024-10-04 07:37:11     Mobiltech Spotify A Spotify bevezette az "Offline Backup"-ot, amely kifejezetten a prémium felhasználók számára készült. Ez a funkció lényegében egy lista, amely az utoljára hallgatott dalokat tartalmazza, és amelyek offline is elérhetők lesznek. A lista automatikusan frissül a hallgatási előzmények alapján. A fizetős felhasználók eddig is letölthettek dalokat offli Érdemes lenne időben leugrani az MI-vonatról az MIT professzora szerint Bitport     2024-10-04 08:01:00     Infotech Vonat Ha lenyugodnának a kedélyek, akkor meg lehetne találni az MI-technológia helyét a megfelelő alkalmazásokban, de ha folytatódik a hiszti, akkor nagyot fog durranni az újabb technológiai lufi – véli Daron Acemoglu. A kutatók szerint a féreglyukak folyamatosan megváltoztatják a valóságunkat titokban Rakéta     2024-10-04 08:00:04     Tudomány Mikroszkopikus méretű féreglyukak lehetnek a megoldásai a kozmológia jelenleg legfontosabb rejtélyeinek – ezek az apró téridőbeli struktúrák ugyanis segíthetnek megmagyarázni, hogy miért kezdett el gyorsulni az univerzum tágulása. Kormányszóvivő: elindult a Digitális Állampolgárság Program Mínuszos     2024-10-04 10:33:25     Infotech Telefon Mobiltelefon A Kormány elindította a Digitális Állampolgárság Programot, amellyel – többek között – már mobiltelefonon is lehetséges személyazonosságot igazolni – közölte Vitályos Eszter kormányszóvivő. Az alkalmazásban minden személyes és gépjármű adatot meg lehet találni egy helyen, illetve néhány gombnyomással foglalható időpont a kormányablakba. Eddig már 1 Azért sem vették komolyan a felmelegedést, mert azt hitték, a klíma csak visszakorrigál a kis jégkorszak után Telex     2024-10-04 10:15:29     Tudomány Válság Klímaváltozás Rácz Lajos klímatörténész szerint helyes és helytelen reakciókat egyaránt találunk a történelemben az éghajlatváltozásra visszavezethető válsághelyzetekre, ezek emlékezete irányt mutathat a jelenkori klímaváltozás kezelésére. Saját időzónája lesz a Holdnak Player     2024-10-04 04:54:01     Tudomány Jelenleg a Holdnak nincs saját időzónája, holott a tudományos és kereskedelmi tevékenységek bővülésével egyre nagyobb szükség lenne egy ilyen szabványosított időrendszerre, amely megkönnyítené a holdi és a földi tevékenységek összehangolását. Terapeutának sem utolsó a ChatGPT, de nem árt vele vigyázni ICT Global     2024-10-04 08:33:59     Infotech Mesterséges intelligencia ChatGPT OpenAI Egyre többen fordulnak a ChatGPT-hez azzal, hogy az MI segítsen nekik eligazodni emberi, esetleg romantikus kapcsolataik között. Az sem ritka, hogy a felhasználók arról faggatják az OpenAI intelligenciáját, miként élhetnének teljesebb életet. Hasznos jelzés érkezik a Google keresőjébe 24.hu     2024-10-04 12:58:33     Infotech Google Az újítás segíthet megelőzni, hogy a felhasználók csaló weboldalakra keveredjenek. Miért lepték el Budapestet a dolmányos varjak? Qubit     2024-10-04 09:26:47     Tudomány A dolmányos vagy kálomista varjú opportunista madár, a nagyváros pedig egy ilyen intelligens állatnak terített asztal. De mit lehet tudni a dolmányosokról, és miért tűnik úgy, hogy meghódították a fővárost? Megint vegzálhatják a Microsoft böngészőjét HWSW     2024-10-04 09:41:28     Infotech Microsoft Böngésző A kisebb riválisok szerint a Microsoft jogosulatlan versenyelőnyhöz juttatja az Edge-t az EU-ban. Rákellenes gyógyszert fedezett fel a mesterséges intelligencia Igényesférfi.hu     2024-10-04 03:04:43     Egészség Mesterséges intelligencia Gyógyszer Rákbetegség A mesterségesintelligencia-alapú gyógyszerkutatással foglalkozó Recursion Pharmaceuticals egyik modern MI-platformja segítségével talált rá arra a molekulára, mely úttörő lehet a különböző daganatos megbetegedések kezelésében. AI-képzés – az új kötelező juttatás? Behaviour     2024-10-04 11:51:03     Karrier Oktatás Mesterséges intelligencia A folyamatos tanulás és fejlődés egyre nagyobb szerepet kap a munkahelyeken, különösen a mesterséges intelligencia területén, amely meghatározó tényezővé vált a munkavállalók megtartásában és a szervezeti siker elérésében. Friss kutatások szerint az AI és más feltörekvő technológiák hatékony alkalmazása, valamint a készségfejlesztésbe történő befek A Visa mindent bevet a csalók ellen Fintech     2024-10-04 06:04:27     Modern Gazdaság Mesterséges intelligencia VISA A Visa felvásárolja a brit Featurespace nevű, mesterséges intelligencia alapú pénzügyi csalás elleni technológiai szolgáltatót. A 2008-ban alapított, cambridge-i székhelyű Featurespace olyan gépi tanulási alapú csalásfelderítési technológiát fejlesztett, amelyet több jelentős pénzintézet is használ. Nehéz felvenni a versenyt a csalókkal A Global An A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

A Spotify offline zenehallgatási funkciót vezetett be ITBusiness     2024-10-04 07:37:11     Mobiltech Spotify A Spotify bevezette az "Offline Backup"-ot, amely kifejezetten a prémium felhasználók számára készült. Ez a funkció lényegében egy lista, amely az utoljára hallgatott dalokat tartalmazza, és amelyek offline is elérhetők lesznek. A lista automatikusan frissül a hallgatási előzmények alapján. A fizetős felhasználók eddig is letölthettek dalokat offli Érdemes lenne időben leugrani az MI-vonatról az MIT professzora szerint Bitport     2024-10-04 08:01:00     Infotech Vonat Ha lenyugodnának a kedélyek, akkor meg lehetne találni az MI-technológia helyét a megfelelő alkalmazásokban, de ha folytatódik a hiszti, akkor nagyot fog durranni az újabb technológiai lufi – véli Daron Acemoglu. A kutatók szerint a féreglyukak folyamatosan megváltoztatják a valóságunkat titokban Rakéta     2024-10-04 08:00:04     Tudomány Mikroszkopikus méretű féreglyukak lehetnek a megoldásai a kozmológia jelenleg legfontosabb rejtélyeinek – ezek az apró téridőbeli struktúrák ugyanis segíthetnek megmagyarázni, hogy miért kezdett el gyorsulni az univerzum tágulása. Kormányszóvivő: elindult a Digitális Állampolgárság Program Mínuszos     2024-10-04 10:33:25     Infotech Telefon Mobiltelefon A Kormány elindította a Digitális Állampolgárság Programot, amellyel – többek között – már mobiltelefonon is lehetséges személyazonosságot igazolni – közölte Vitályos Eszter kormányszóvivő. Az alkalmazásban minden személyes és gépjármű adatot meg lehet találni egy helyen, illetve néhány gombnyomással foglalható időpont a kormányablakba. Eddig már 1 Azért sem vették komolyan a felmelegedést, mert azt hitték, a klíma csak visszakorrigál a kis jégkorszak után Telex     2024-10-04 10:15:29     Tudomány Válság Klímaváltozás Rácz Lajos klímatörténész szerint helyes és helytelen reakciókat egyaránt találunk a történelemben az éghajlatváltozásra visszavezethető válsághelyzetekre, ezek emlékezete irányt mutathat a jelenkori klímaváltozás kezelésére. Saját időzónája lesz a Holdnak Player     2024-10-04 04:54:01     Tudomány Jelenleg a Holdnak nincs saját időzónája, holott a tudományos és kereskedelmi tevékenységek bővülésével egyre nagyobb szükség lenne egy ilyen szabványosított időrendszerre, amely megkönnyítené a holdi és a földi tevékenységek összehangolását. Terapeutának sem utolsó a ChatGPT, de nem árt vele vigyázni ICT Global     2024-10-04 08:33:59     Infotech Mesterséges intelligencia ChatGPT OpenAI Egyre többen fordulnak a ChatGPT-hez azzal, hogy az MI segítsen nekik eligazodni emberi, esetleg romantikus kapcsolataik között. Az sem ritka, hogy a felhasználók arról faggatják az OpenAI intelligenciáját, miként élhetnének teljesebb életet. Hasznos jelzés érkezik a Google keresőjébe 24.hu     2024-10-04 12:58:33     Infotech Google Az újítás segíthet megelőzni, hogy a felhasználók csaló weboldalakra keveredjenek. Miért lepték el Budapestet a dolmányos varjak? Qubit     2024-10-04 09:26:47     Tudomány A dolmányos vagy kálomista varjú opportunista madár, a nagyváros pedig egy ilyen intelligens állatnak terített asztal. De mit lehet tudni a dolmányosokról, és miért tűnik úgy, hogy meghódították a fővárost? Megint vegzálhatják a Microsoft böngészőjét HWSW     2024-10-04 09:41:28     Infotech Microsoft Böngésző A kisebb riválisok szerint a Microsoft jogosulatlan versenyelőnyhöz juttatja az Edge-t az EU-ban. Rákellenes gyógyszert fedezett fel a mesterséges intelligencia Igényesférfi.hu     2024-10-04 03:04:43     Egészség Mesterséges intelligencia Gyógyszer Rákbetegség A mesterségesintelligencia-alapú gyógyszerkutatással foglalkozó Recursion Pharmaceuticals egyik modern MI-platformja segítségével talált rá arra a molekulára, mely úttörő lehet a különböző daganatos megbetegedések kezelésében. AI-képzés – az új kötelező juttatás? Behaviour     2024-10-04 11:51:03     Karrier Oktatás Mesterséges intelligencia A folyamatos tanulás és fejlődés egyre nagyobb szerepet kap a munkahelyeken, különösen a mesterséges intelligencia területén, amely meghatározó tényezővé vált a munkavállalók megtartásában és a szervezeti siker elérésében. Friss kutatások szerint az AI és más feltörekvő technológiák hatékony alkalmazása, valamint a készségfejlesztésbe történő befek A Visa mindent bevet a csalók ellen Fintech     2024-10-04 06:04:27     Modern Gazdaság Mesterséges intelligencia VISA A Visa felvásárolja a brit Featurespace nevű, mesterséges intelligencia alapú pénzügyi csalás elleni technológiai szolgáltatót. A 2008-ban alapított, cambridge-i székhelyű Featurespace olyan gépi tanulási alapú csalásfelderítési technológiát fejlesztett, amelyet több jelentős pénzintézet is használ. Nehéz felvenni a versenyt a csalókkal A Global An A további adásainkat keresd a podcast.hirstart.hu oldalunkon.

Hello folks and welcome to This Is Robotics. I'm your host and fellow companion, Tom Green.The last half of 2024 is upon us, robotics-driven automation is in rapid ascendancy once again, especially now since 2024 is showing how robotics engages with GenAI, and how prompt engineering is significantly increasing the ease of adoption for robots everywhere. Last month, we gave you a longish one-hour show, which was necessary for it was meant to support my keynote address at SuperTechFT in San Francisco.  If you have yet to listen to it, it's Episode # 31 and deals with how quickly computer code has capitulated to prompt engineering…and why. Plus, the new breed of workers on the rise who are being hailed as the “New Collar” generation of workers.This month, we are listening to our global fans for feedback. We have a global fan base in 68 countries according to Buzzsprout stats. A fangirl Celina from the Philippines wants us to reprise a woman's show. Specifically, the rise of Alice Zhang (Verge Genomics) and her pursuit of answers to neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. Thank you, Celina for also pointing out how this story highlights how human insight creates the technical challenge and how LLMs are then employed to reveal a way forward for bio research. For Alice, it was robotics and LLMs cracking the code for ALS.During Alice's piece, she laments how broken bio research is and why. Which leads to our second fan request from Martin in Augsburg, Germany, who was fascinated with robotics in bio labs working with AI in what he calls Pharma 4.0. New drug research and discovery companies with strange, new names like Recursion Pharmaceuticals, Arctoris, Insitro, Relay Therapeutics, and Insilico Medicine are forging the way. Martin, good pick.We lead off this month humankinds almost innate fascination and attraction to humanoid robots. Why is that? We let a half dozen experts offer up some truly interesting insights and theories on just why that is. Those insights are wrapped up in a show about human attraction to robots where we commemorate National Kiss & Make up Day which is coming up in August.Okay, strap on your earphones or pop in your earbuds, which Buzzsprout tells us 3,000 people do daily worldwide to listen to This Is Robotics. We're thrilled you can join us today. Thanks and welcome.https://asianroboticsreview.com/home591-html

In der heutigen Folge von “Alles auf Aktien” sprechen die Finanzjournalisten Laurin Meyer und Nando Sommerfeldt über das Orakel von Washington, Lieferprobleme bei Airbus und den Tag der Meme-Stocks. Außerdem geht es um Vonovia, LEG, Aroundtown, TAG, Infineon, Gamestop, AMC Entertainment, Koss, Nvidia, Arm Holdings, Recursion Pharmaceuticals, SoundHound, Softbank und Nano-X Imaging. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of ACM ByteCast, Rashmi Mohan hosts ACM A.M. Turing Award laureate Yoshua Bengio, Professor at the University of Montreal, and Founder and Scientific Director of MILA (Montreal Institute for Learning Algorithms) at the Quebec AI Institute. Yoshua shared the 2018 Turing Award with Geoffrey Hinton and Yann LeCun for their work on deep learning. He is also a published author and the most cited scientist in Computer Science. Previously, he founded Element AI, a Montreal-based artificial intelligence incubator that turns AI research into real-world business applications, acquired by ServiceNow. He currently serves as technical and scientific advisor to Recursion Pharmaceuticals and scientific advisor for Valence Discovery. He is a Fellow of ACM, the Royal Society, the Royal Society of Canada, Officer of the Order of Canada, and recipient of the Killam Prize, Marie-Victorin Quebec Prize, and Princess of Asturias Award. Yoshua also serves on the United Nations Scientific Advisory Board for Independent Advice on Breakthroughs in Science and Technology and as a Canada CIFAR AI Chair.  Yoshua traces his path in computing, from programming games in BASIC as an adolescent to getting interested in the synergy between the human brain and machines as a graduate student. He defines deep learning and talks about knowledge as the relationship between symbols, emphasizing that interdisciplinary collaborations with neuroscientists were key to innovations in DL. He notes his and his colleagues' surprise in the speed of recent breakthroughs with transformer architecture and large language models and talks at length about about artificial general intelligence (AGI) and the major risks it will present, such as loss of control, misalignment, and nationals security threats. Yoshua stresses that mitigating these will require both scientific and political solutions, offers advice for researchers, and shares what he is most excited about with the future of AI.

Nvidia, a prominent artificial intelligence technology company, showcases interest in healthcare through launching new AI tools and partnering with Johnson & Johnson and GE Healthcare at its 2024 GTC conference. The adoption of AI in drug discovery speeds up the process while reducing costs. Nvidia's BioNeMo platform targets drug development and offers cost savings beyond that area. The company has invested $50 million in Recursion Pharmaceuticals and partnered with Roche's Genentech, Schrödinger, and others for medication development and treatment protocol improvement. AI is transforming healthcare by impacting drug development, cost reduction, and patient care through companies like Nvidia. --- Send in a voice message: https://podcasters.spotify.com/pod/show/tonyphoang/message

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Philipp Vetter und Holger Zschäpitz über die Rückkehr der YOLO-Trader, krasse Zahlen bei Coinbase und Nvidias König-Midas-Effekt. Außerdem geht es um Apple, Microsoft, Commerzbank, Applied Materials, The Trade Desk, ARM, Recursion Pharmaceuticals, Soundhound AI, Nano-X, TuSimple, Digital World Acquisition, Jumia, Stellantis, Renault, Volkswagen, Porsche, Invesco EQQQ Nasdaq-100 (WKN: 801498), iShares Core MSCI World (WKN: A0RPWH) Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Joining us today in The Deep End is Viswa Colluru, the CEO & Founder of Enveda Biosciences. Enveda has raised $175M in their quest to translate nature into medicine. Before founding Enveda, Viswa obtained a PhD in cellular and molecular biology, and started his career as a product manager at Recursion Pharmaceuticals. As our first guest in this series focusing on longevity and health, we speak to Viswa on why nature holds the great untapped potential for new drug discovery, why most drugs don't work in human trials and what role artificial intelligence will play in unlocking biological and chemical data. We hope this conversation will give you a deep insight into nuances of the pharmaceutical industry, what the future holds for drug discovery and his advice for founders interested in this space.

Ira Jersey, Chief US interest rate strategist for Bloomberg Intelligence, discusses the day's latest eco data. Kara Murphy, CIO at Kestra Investment Management, joins us in studio to talk stocks and investing. Anneka Treon, Chief Economist at Van Lanschot Kempen, joins to give her global macro view and outlook for the US and global inflation.  Alison Williams, Senior Global Banks & Asset Managers analyst with Bloomberg Intelligence, and Herman Chan, Senior Regional Banks analyst with Bloomberg Intelligence, join for an earnings breakdown of the big banks and regionals. Chris Gibson, CEO at Recursion Pharmaceuticals, joins to discuss last week's big stock jump on news Nvidia invested $50 million into his company. Hosted by Paul Sweeney and Madison Mills. See omnystudio.com/listener for privacy information.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Lena Zimmermann und Holger Zschäpitz über einen teuer erkauften Kurssprung bei About You, einen KI-Hype im Biotech-Sektor und eine fette Gewinnwarnung bei BASF. Außerdem geht es um Delta, American Airlines, United Airlines, Lanxess, Evonik, Continental, Nvidia, Recursion Pharmaceuticals, Palantir, Exscientia, Relay Therapeutics, Schrodinger, AbCellera Biologics Dominos Pizza, Uber, BP, TotalEnergies, Amazon, Eckert& Ziegler, United Internet, Warner Bros Discovery, Moderna, Nagarro, JD.com, Vonovia, Bayer, VERBIO Vereinigte BioEnergie, Encavis, Delivery Hero, AT&T, Kontron, Befesa, Cancom, Siemens Energy, PDD Holdings, Fresenius, Deutsche Bank, SolarEdge Technologies, Zalando, Deutsche Lufthansa, MercadoLibre, Humana, HelloFresh, LANXESS, VF Corp, Volkswagen, Duerr, Bio-Rad Laboratories, Organon & Co, Evotec und Merck. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Das Buch zum Podcast? JETZT BESTELLEN. Lieber als Newsletter? Geht auch. About You liebt das adjustierte EBITDA. Zalando liebt mit. Ansonsten ist Inflation tief und Partnerschaft wird großgeschrieben: Bei Domino's & Uber, bei Roku & Shopify, bei Nvidia & Recursion Pharmaceuticals. Achja: Bitcoin For President. Jeff Bezos und Mark Zuckerberg tragen seine grauen T-Shirts, seine Mitarbeiter dürfen nach 17:30 keine Mails mehr schicken und deshalb ist Brunello Cucinelli (WKN: A1JWYK) Milliarden wert. ChatGPT-Gründer bringt Künstliche Intelligenz, unendliche Energie und bedingungsloses Krypto-Einkommen für die ganze Welt. Diesen Podcast vom 13.07.2023, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Also, Domino's Pizza shares rose 11% after the company said it will list its menu on Uber's Eats and Postmates apps in 28 markets. Recursion Pharmaceuticals shares rose 78% after the company said Nvidia is investing $50 million in its drug-discovery companies. J.R. Whalen reports. Learn more about your ad choices. Visit megaphone.fm/adchoices

Li-Cycle CEO Ajay Kochhar (LICY) explains how he helped invent a new way to recycle lithium-ion batteries while firing back at skeptical analysts and short-sellers. Recursion Pharmaceuticals (RXRX) deploys artificial intelligence with the help of Nvidia (NVDA). Constellation Brands (STZ) explains why Modelo is winning as consumers shift to more expensive alcohol. Paychex (PAYX) delves into the plight of small business, profitably. And LOTS more from Rochester, New York! The Drill Down with Cory Johnson offers a regular look at the business stories behind stocks on the move. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this week's Tech Nation, conjure up images of test tubes, and replace it with tiny wells on index-card-size trays, and robots moving them to and fro. Dr. Chris Gibson, the CEO of Recursion Pharmaceuticals, tells us about their effort to analyze all of human biology, and the drugs in their very own pipeline. Then, who knew Sociology and Criminology were linked? University of Denver professor Jared Del Rosso talks about his book “Denial … How We Hide, Ignore, and Explain Away Problems””, and answers the question – will the election deniers *always* believe the 2020 presidential election was stolen?

We speak to Recursion Pharmaceuticals about its use of artificial intelligence, data science, and robotics to create medicinal drugs more efficiently than before and at a lower cost.In this episode, Recursion's co-founder and CEO Chris Gibson tells Scottish Mortgage's manager Tom Slater how the firm uses cutting-edge technologies to create novel insights about biology and chemistry that can lead to potential treatments. They discuss why Recursion's methods mean it can target rare diseases, which might not make financial sense for more traditional drug companies to explore. In addition, they discuss the importance of company culture and taking time to onboard new recruits.Recursion Pharmaceuticals was founded 10 years ago. It performs millions of experiments every week using high-precision robotics. Researchers then analyse the results using machine learning techniques to home in on promising drug candidates.The company already has five drugs in clinical trials. One of these is a potential treatment for cerebral cavernous malformations, which are abnormally shaped brain or spinal cord blood vessels. These can cause seizures and problems with balance and walking. As its technology improves over time, Recursion hopes to tackle a broader range of diseases, potentially improving millions of people's lives.Check the podcast description to ensure this content is suitable for you. Your capital is at risk.Read more:Recursion provides business updates and reports fourth quarter and fiscal year 2022 financial resultsCredits:Presenter: Claire ShawAudio production agency: ListenProducer: Phil SansomExecutive producer: Suzy GrantProduction manager: Niamh KiddEditorial lead: Malcolm Borthwick Hosted on Acast. See acast.com/privacy for more information.

After ten years of working on a specific disease, Chris Gibson's graduate school lab tested their treatment theory on an animal model. It not only didn't work, it actually made the animals worse. The experience prompted Gibson to look into how other tools and techniques could be brought to bear on biological programs. And so he quit medical school to co-found Recursion Pharmaceuticals where he is now CEO.  In this episode, Gibson sits down with host Stan Gloss of BioTeam, about Recursion's mission to decode biology, radically improve lives, and set big goals to innovate across every stage of drug discovery. “If you set goals that are easily achieved, you default to using tools that have been used in the past. The only way you can force yourself to use new tools is if you set goals that are very hard to achieve if not seemingly impossible,” Gibson said. He talks about the company's use of 'omics technologies to answer the industry's present and future questions, their highly automated wet lab with robots, and Recursion's use of machine learning to understand biology as a complete system. Gibson also discusses the company's purpose-built datasets and the culture-first approach that helps foster more agility relative to larger, older pharmaceutical giants.Links from this episode:  Bio-IT World BioTeam Recursion Recursion's Vision for the New Shape of Drug Discovery    Trends from the Trenches boiler: Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what's coming next.

On this week's Tech Nation, conjure up images of test tubes, and replace it with tiny wells on index-card-size trays, and robots moving them to and fro. Dr. Chris Gibson, the CEO of Recursion Pharmaceuticals, tells us about their effort to analyze all of human biology, and the drugs in their very own pipeline. Then, who knew Sociology and Criminology were linked? University of Denver professor Jared Del Rosso talks about his book “Denial … How We Hide, Ignore, and Explain Away Problems””, and answers the question – will the election deniers *always* believe the 2020 presidential election was stolen?

You may have heard of facial recognition technology but what about face recognition for cells in your body? This is one of the many technologies that Recursion Pharmaceuticals uses as part of its industrialisation of drug discovery. Deep learning algorithms can tell the difference between health and diseased human cells and use this to identify new medicines.“The opportunity is to industrialise drug discovery,” says  Recursion Pharmaceuticals' president Tina Larson. “The best of the tech industry and the best of all of these tools - like CRISPR - that are in the life science industry now, to really change the way we discover medicine.”Tina Larson, President, Recursion Pharmaceuticals was in conversation with Ashley McKimm, Editor-in-chief of BMJ Innovations at the British Medical Journal on the HealthConf stage at Web Summit 2021. Use promo code 'TNS' for 10% off your #CollisionConf ticket now.

Listen now | Episode 73 Follow me @samirkaji for my thoughts on the venture market, with a focus on the continued evolution of the VC landscape.This week we have friend-of-the-pod Guy Perelmuter, founder of GRIDS Capital, a firm based in Sao Paulo, Brazil that invests in funds and direct investments into deep tech startups. GRIDS has the thesis statement, “Science is our Business. Business is our Science,” and its portfolio includes a number of funds as well as directs into Desktop Metal, Recursion Pharmaceuticals, Instrumental, Matterport, Esper, and Momentus Space. Subscribe at ventureunlocked.substack.com

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Personalized Medicine For Real, published by sarahconstantin on the LessWrong. I was part of the founding team at MetaMed, a personalized medicine startup. We went out of business back in 2015. We made a lot of mistakes due to inexperience, some of which I deeply regret. I'm reflecting on that now, because Perlara just went out of business, and they got a lot farther on our original dream than we ever did. Q-State Biosciences, which is still around, is using a similar model. The phenomenon that inspired MetaMed is that we knew of stories of heroic, scientifically literate patients and families of patients with incurable diseases, who came up with cures for their own conditions. Physicist Leo Szilard, the “father of the atom bomb”, designed a course of radiation therapy to cure his own bladder cancer. Computer scientist Matt Might analyzed his son's genome to find a cure for his rare disorder. Cognitive scientist Joshua Tenenbaum found a personalized treatment for his father's cancer. So, we thought, could we try to scale up this process to help more people? In Lois McMaster Bujold's science fiction novels, the hero suffers an accident that leaves him with a seizure disorder. He goes to a medical research center and clinic, the Durona Group, and they design a neural prosthetic for him that prevents the seizures. This sounds like it ought to be a thing that exists. Patient-led, bench-to-bedside drug discovery or medical device engineering. You get an incurable disease, you fund scientists/doctors/engineers to discover a cure, and now others with the disease can also be cured. There's actually a growing community of organizations trying to do things sort of in this vein. Recursion Pharmaceuticals, where I used to work, does drug discovery for rare diseases. Sv.ai organizes hackathons for analyzing genetic data to help patients with rare diseases find the root cause. Perlara and Q-state use animal models and in-vitro models respectively to simulate patients' disorders, and then look for drugs or gene therapies that reverse those disease phenotypes in the animals or cells. Back at MetaMed, I think we were groping towards something like this, but never really found our way there. One reason is that we didn't narrow our focus enough. We were trying to solve too many problems at once, all called “personalized medicine.” Personalized Lifestyle Optimization Some “personalized medicine” is about health optimization for basically healthy people. A lot of it amounts to superficial personalization on top of generic lifestyle advice. Harmless, but more of a marketing thing than a science thing, and not very interesting from a humanitarian perspective. Sometimes, we tried to get clients from this market. I pretty much always thought this was a bad idea. Personalized Medicine For All Some “personalized medicine” is about the claim that the best way to treat even common diseases often depends on individual factors, such as genes. This was part of our pitch, but as I learned more, I came to believe that this kind of “personalization” has very little applicability. In most cases, we don't know enough about how genes affect response to treatment to be able to improve outcomes by stratifying treatments based on genes. In the few cases where we know people with different genes need different treatments, it's often already standard medical practice to run those tests. I now think there's not a clear opportunity for a startup to improve the baseline through this kind of personalized medicine. Preventing Medical Error Some of our founding inspirations were the work of Gerd Gigerenzer and Atul Gawande, who showed that medical errors were the cause of many deaths, that doctors tend to be statistically illiterate, and that systematizing tools like checklists and statistical prediction rules save...

Recursion is a clinical state biology company decoding Balaji by integrating technological innovations across biology chemistry and automation.

Heute möchten wir euch Recursion Pharmaceuticals vorstellen. Ein Biotechnologie-Unternehmen in der klinischen Phase, das versucht die Geheimnisse der Biologie zu entschlüsseln, indem es technologische Innovationen aus den Bereichen Biologie, Chemie, Automatisierung, Data Science und Engineering integriert, um letztlich, die Arzneimittelforschung zu industrialisieren. 

How do startups decide between trade secret and patent protection? What does the analysis look like? Sandy Chan, Executive Director & General Counsel at IP Counsel Cafe speaks with Kevin Brown, Vice President of IP at Recursion Pharmaceuticals, a clinical-stage biotechnology company that combines experimental biology and automation with artificial intelligence to discover potential drugs; and Stephanie Southwick, Legal Counsel and Investment Manager at Omni Bridgeway, a global leader in dispute resolution finance.

Nan is a managing director at Obvious Ventures, where he invests in companies solving the world’s biggest problems in sustainable systems, healthy living, and people power. At Obvious, his investments have included LabGenius, Recursion Pharmaceuticals, Darwin AI, Octave Health, Zymergen, and Planet. Prior to joining Obvious, Nan has had a mix of technology, investing, and entrepreneurship experiences including early stage tech investments at Innovation Endeavors, Product, Operations, and Finance at Gigwalk, VC and management consulting at Bain, and PM at Microsoft. Nan is also an adjunct lecturer at Stanford where he teaches a course on symbolic systems in VC and entrepreneurship.Topics:- Computational biology investments- Understanding the biology of investments- Applying digital approaches to biology- Addressing computational drug design skeptics- Managing fund cycle expectations in deep tech investing- East vs west coast investment mindsets

Conventional drug discovery ignores the spatial relationships between cells when assessing the effects of drugs. I talk with Imran Haque, VP of Data Science at Recursion Pharmaceuticals, about their data-first approach that combines "cell painting" with deep learning to assess changes in cellular morphology, thus providing a crucial lens into the molecular wirings of a given drug's mechanism of action. We discuss his team's work in repurposing therapies to tackle COVID-19 and what it takes to successfully merge deep learning with cellular images in a way that yields therapies. Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary --- Support this podcast: https://anchor.fm/the-data-pulse/support

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host. Genialis is focused on data integration and predictive modeling of disease biology to help accelerate the discovery and de-risk the development of novel therapeutics. Today our guest is Tina Larson. Tina is COO of Recursion Pharmaceuticals, where she is tasked with building the team, the operations and the culture to tackle Recursion’s audacious goals. Tina has over 20 years of experience in the biopharmaceutical industry, and was recently awarded the 2019 Distinguished Alumni Award from her alma mater Colorado State University. In this episode, we talk about the language of multidisciplinary teams, recruiting top talent while fostering inclusivity, and the promise of melding tech and biology to advance treatments at unprecedented scale.

With confidence he attributes to his free-range childhood, Chris Gibson has followed his instincts and his heart, stepping away from the MD/PhD program in which he’s enrolled to co-found and lead Recursion Pharmaceuticals, one of the buzziest companies bringing AI to drug development. In mid-July, Recursion closed a $121M Series C, bringing their valuation ever […]

Merging machine learning and AI for experimental biology at an unprecedented scale

The Bottom Line (Original Air Date: May 15, 2018) — Chris Gibson, Co-Founder and CEO of Recursion Pharmaceuticals.  You may have heard of Recursion Pharmaceuticals in the media for its push to create 100 drug treatments in 10 years, focusing first on cures for rare diseases. The company’s approach is to combine drug repurposing efforts with […]

Harry asks Dr. Ron Alfa, vice president of discovery and product at Recursion Pharmaceuticals, what efficiencies could be achieved and what problems could be solved if data science were applied to drug discovery. This is Part 4 of a special six-part series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October 2018. How to rate MoneyBall Medicine on iTunes with an iPhone, iPad, or iPod touch: Launch the "Podcasts" app on your device. If you can't find this app, swipe all the way to the left on your home screen until you're on the Search page. Tap the search field at th top and type in "Podcasts." Apple's Podcasts app should show up in the search results. Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner. Type MoneyBall Medicine into the search field and press the Search button. In the search results, click on the MoneyBall Medicine logo. On the next page, scroll down until you see the Ratings & Reviews section. Below that you'll see five purple stars. Tap the stars to rate the show. Scroll down a little farther. You'll see a purple link saying "Write a Review." On the next screen, you'll see the stars again. You can tap them to leave a rating, if you haven't already. In the Title field, type a summary for your review. In the Review field, type your review. When you're finished, click Send. That's it, you're done. Thanks!

Recursion Pharmaceuticals is reinventing the drug discovery process by turning biology into a data science problem. The company has set an audacious goal for itself of developing 100 drugs in 10 years. Though Recursion initially focused on repurposing existing drugs to treat rare diseases, it has expanded its work into new disease areas and is looking at new chemical entities as well. We spoke to Chris Gibson, founder and CEO of Recursion, about the approach the company is taking, the challenges of mixing biologists and data scientists together, and why he's holding fast to his goal of attaining an unparalleled level of drug development efficiency through the use of artificial intelligence.

Christopher Gibson. He’s the co-founder and CEO of Recursion Pharmaceuticals, a biotech company leveraging the latest automation, computation and biological tools to perform drug discovery at scale. Chris holds a BS in bioengineering, a BA in managerial studies, and a bioengineering PhD from the University of Utah. Famous Five: Favorite Book? – The Hard Thing About Hard Things What CEO do you follow? –  Perry Fell Favorite online tool? — Slack Do you get 8 hours of sleep?— 5.3 to 5.4 If you could let your 20-year old self, know one thing, what would it be? – Chris wished he knew where he was going to go so he could get to where he is now, faster   Time Stamped Show Notes: 01:42 – Nathan introduces Chris to the show 02:12 – Recursion shortcuts the long, arduous path of drug discovery into the market 02:24 – Recursion combines the best elements of biology, automation, and computation 02:34 – Recursion partners with large pharmaceutical companies 02:45 – Recursion partnered with Sanofi Genzyme 02:51 – Sanofi had drugs that didn’t end up in the market 03:10 – The challenges involved in being target-based 04:00 – Recursion earns from partnerships and royalties 04:20 – Recursion also has an internal pipeline for the drugs that they’ve developed themselves 04:43 – Recursion doesn’t earn from the internal pipeline 05:51 – Recursion and what they receive from their partners 06:28 – There are partnerships with very, little upfront 06:34 – There are partnerships that have 8 figures, upfront 06:46 – The number of scientists that will work on the drug is also considered 07:22 – If Recursion is successful with their deals, they get royalties 08:38 – The royalties’ lifeline 08:56 – Recursion has 40 people  09:25 – Recursion was launched in 2013 09:34 – They sat in their office until January 2014 10:01 – Chris was part of a program where he was paid a stipend, so he broke even 10:20 – Chris’ parents were excited about his PhD 10:37 – Recursion has raised $19M in equity and $5M non-diluted from grants and private foundations 11:28 – Recursion’s valuation as a platform company 12:14 – If Recursion will be successful, they will impact the society in a big way 12:41 – It is vision-based 12:54 – First year revenue was 6 figures 13:12 – “Our deals have been strategic in terms of the way we put them together” 13:45 – 2017 target 16:10 – The Famous Five   3 Key Points: Different sources of revenue benefit a company. The valuation of your company depends on how your company is currently performing and how well they will perform in the industry. First year revenue isn’t always nil.   Resources Mentioned: The Top Inbox  – The site Nathan uses to schedule emails to be sent later, set reminders in inbox, track opens, and follow-up with email sequences Organifi – The juice was Nathan’s life saver during his trip in Southeast Asia Klipfolio – Track your business performance across all departments for FREE Acuity Scheduling – Nathan uses Acuity to schedule his podcast interviews and appointments Host Gator – The site Nathan uses to buy his domain names and hosting for the cheapest price possible Audible – Nathan uses Audible when he’s driving from Austin to San Antonio (1.5-hour drive) to listen to audio books Freshbooks – Nathan doesn’t waste time so he uses Freshbooks to send out invoices and collect his money. Get your free month NOW Show Notes provided by Mallard Creatives

Recursion Pharmaceuticals has set the audacious goal for itself of developing 100 drugs in 10 years for rare diseases. The company, focused on repurposing compounds abandoned in clinical development by other drugmakers, thinks it can achieve this by a fundamentally different approach to drug development than the industry’s traditional process of screening compounds against potential disease targets. We spoke to Chris Gibson, founder and CEO of Recursion, about the approach his company is taking, whether rare diseases particularly lend themselves to it, and whether it has implications more broadly for drug development.

Recursion Pharmaceuticals has developed a new method of drug discovery that they claim will lead to 100 new treatments for hard-to-treat rare genetic diseases within 10 years. Christopher Gibson, Ph.D., CEO of Recursion, explains the technology that allows them to rapidly screen through hundreds of candidate treatments for nearly any genetic disease. He also describes why they are opting to screen through old, already existing drugs, instead of developing new ones. Their approach has already led to identification of a potential therapeutic for cerebral cavernous malformation, a finding recently published in Circulation . Learn more.